

72 87. (New) A composition comprising a polypeptide according to any one of claims 88 and 81, in combination with a non-specific immune response enhancer.
65 66

73 88. (New) A composition according to claim 87, wherein the non-specific immune response enhancer is an adjuvant.

74 89. (New) A composition according to claim 87, wherein the non-specific immune response enhancer induces a predominantly Type I response.

72

B) condlo

REMARKS

Favorable consideration of the subject application is respectfully requested in view of the above amendments. Following the amendments, claims 80-89 are under consideration.

The pending claims have been amended in order to remove reference to non-elected inventions and/or species, and to focus prosecution on aspects of the invention presently of most commercial interest to the assignee of the subject application. Specifically, claims 1-3, 14-17 and 64 have been cancelled from the application and claims 80-89 have been added. Applicants believe that claim 64 was incorrectly included with the claims of Group I in the Restriction Requirement mailed March 29, 2001.

Newly added claim 80 is drawn to polypeptides comprising a portion of the elected species (SEQ ID NO:113) with claim 81 being drawn to such polypeptides, wherein the polypeptide comprises a sequence of SEQ ID NO:554, 558, 562, 566 and 573. As shown in Figure 9 of the specification as originally filed, SEQ ID NO:554, 558, 562, 566 and 573 represent extracellular domains of SEQ ID NO:113. Newly added claims 82 and 84 are drawn to polypeptides comprising a portion of a sequence having at least 90% and 95% identity, respectively, to SEQ ID NO:113, wherein the polypeptide is over-expressed in prostate tissue compared to all other normal tissues. Claims 83 and 85 are drawn to such polypeptides, wherein the polypeptide comprises a sequence having 90% or 95% identity, respectively to a sequence of

B

SEQ ID NO:554, 558, 562, 566 and 573, and is over-expressed in prostate tissue compared to all other normal tissues. It is urged that support for newly added claims 82-85 may be found, for example, on page 31, lines 25-27, and page 64, line 29 through page 65, line 17, of the specification as originally filed. Newly added claim 86 is drawn to compositions comprising a polypeptide of claims 82-85.

Claim 87 is substantially parallel to original claim 14 and is now dependent on newly added claims 80 and 81. Claims 88 and 89 parallel original claims 15 and 16.

It is urged that support for all the above amendments may be found throughout the specification as originally filed, and that none of these amendments constitute new matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Early consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC


Jeffrey C. Pepe, Ph.D.
Registration No. 46,985

Enclosures:

Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031

U:\sharons\210121\427c9
D:\NRPOTH\Manage\SHARONS\189785_1.DOC